cellular prion protein mediates impairment synaptic plasticity amyloid-beta oligomers 
pathological hallmark alzheimers disease accumulation insoluble plaque containing amyloid-beta peptide - amino acid residues1 prefibrillar soluble oligomers amyloid-beta recognized early key intermediates alzheimers-disease-related synaptic dysfunction2- nanomolar concentrations soluble amyloid-beta oligomers block hippocampal long-term potentiation7 cause dendritic spine retraction pyramidal cells58 impair rodent spatial memory2 soluble amyloid-beta oligomers prepared chemical syntheses transfected cell culture supernatants transgenic mouse brain human alzheimers disease brain2479 together data imply high-affinity cell-surface receptor soluble amyloid-beta oligomers neurons-one central pathophysiological process alzheimers disease identify cellular prion protein prpc amyloid-beta-oligomer receptor expression cloning amyloid-beta oligomers bind nanomolar affinity prpc interaction require infectious prpsc conformation synaptic responsiveness hippocampal slices young adult prp null mice normal amyloid-beta oligomer blockade long-term potentiation absent anti-prp antibodies prevent amyloid-beta-oligomer binding prpc rescue synaptic plasticity hippocampal slices oligomeric amyloid-beta thus prpc mediator amyloid-beta-oligomer-induced synaptic dysfunction prpc-specific pharmaceuticals may therapeutic potential alzheimers disease 
